Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

1075 - Filipino BRCA CTCs & gene expression: Descriptive study, feasibility and utility


19 Dec 2015


Poster presentation 1


Herdee Gloriane Luna


Annals of Oncology (2015) 26 (suppl_9): 8-15. 10.1093/annonc/mdv518


H.G. Luna1, G.R. Cristal-Luna1, F. Heralde III2, M..T. Barzaga2

Author affiliations

  • 1 Internal Medicine, Section Of Medical Oncology, National Kidney and Transplant Institute, 1102 - Quezon City/PH
  • 2 Molecular Diagnostics And Cellular Therapeutics Laboratory, Lung Center of the Philippines, 1102 - Quezon City/PH


Abstract 1075


CTC count with gene expression profiling is a novel breast cancer biomarker with potential for personalized treatment. Its feasibility & clinical utility in low-resource centers has not been evaluated. Facilitating this technology poses numerous challenges: cost, availability, undefined risk-benefit ratio & outcome among Filipinos & not yet a standard approach. Primary objective is to describe CTC count & gene expression profile of Filipino breast cancer patients. This is the first Filipino data on CTCs.


Charts of breast cancer patients who underwent the procedure at participating hospitals from January 2014 to August 2015 were reviewed. CTC count was done on blood extracts using EpCam-targeted magnetic beads, followed by immunofluorescence validation of cell surface markers (i.e., DAPI+ CD45- CK+). Gene expression profiling was done through Real Time PCR of buffy coat RNA extracts using three tumor associated-genes (i.e., CD133, CK19 & MUC1). Tumor subtypes were determined by IHC. FISH was done in Her2 equivocal findings.


74 patients underwent CTC evaluation, of which, 47 were eligible for study. Median age was 57 +/- 9. Stages I, II, III, IV account for 11%, 38%, 34% & 17% respectively. Luminal A, Luminal B Her2 negative, Luminal B, Her2 enriched, TNBC represent 51%, 2%, 23%, 13% & 11% respectively. CTC count ranged from 0-29 (mean: 2). CTC counts were determined: post standard of care (89%), during surveillance (9%) & at baseline (2%). CTC count after 6 months in 23%, showed values from 0-3 (mean: 1.1).

CD133, CK19 & MUC1 Expression Among BRCA Subtypes N 19

n % Upregulated
Luminal A N 7 4 57 MUC1
2 29 CD133 & MUC1
1 14 none
Luminal B Her2 neg N 1 1 100 MUC1
Luminal B N 4 3 75 MUC1
1 25 CK19
Her2 enriched N 4 2 50 MUC1
1 25 CK19
1 25 none
TNBC N 3 2 67 MUC1
1 33 CD133 & MUC1

Median turn-around time from request to result was 7 days (range 5-10).


CTC with gene expression profiling is feasible in low-resource center. Its clinical usefulness reflects aggressive monitoring & treatment strategies in elevated CTC count (>3), upregulated CD133, CK19 & MUC1. Further research is needed to overcome challenges, increase utility, gain gene expression knowledge among Filipinos, provide better leads for treatment & improve survival.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings